文献速递疼痛医学

计算机辅助发现新型Nav1.7抑制剂用于治疗疼痛和瘙痒

Computer-aided Discovery of a New Nav1.7 Inhibitor for Treatment of Pain and Itch.
PubMed 文献 · Anesthesiology · 2020-01-01

该化合物在体外抑制钠电流,并在小鼠炎症痛、神经病理痛和瘙痒模型中显示镇痛和抗瘙痒活性。

要点

  • DA-0218抑制Nav1.7钠电流的IC50为0.74 μM(95% CI, 0.35-1.56 μM)。
  • 腹腔和鞘内注射DA-0218分别减少小鼠福尔马林II相疼痛行为76%和80%。
  • 鞘内注射DA-0218减轻紫杉醇诱导的机械性异常疼痛和组胺诱导的急性瘙痒。

核心结论

  • 计算机辅助药物发现方法获得新型Nav1.7抑制剂DA-0218,在小鼠模型中具有镇痛和抗瘙痒活性。

研究设计与样本

  • 体外实验使用表达Nav1.7的HEK293细胞及小鼠和人背根神经节神经元。
  • 体内实验采用福尔马林炎症痛模型、紫杉醇神经病理痛模型、组胺诱导瘙痒模型和小鼠淋巴瘤慢性瘙痒模型。

主要发现

  • 筛选出9个化合物进行体外评估,其中4个抑制Nav1.7钠电流≥29%(P < 0.05)。
  • DA-0218抑制Nav1.7钠电流80%,IC50为0.74 μM(95% CI, 0.35-1.56 μM)。
  • DA-0218对表达Nav1.5的HEK293细胞无影响。
  • DA-0218在小鼠和人背根神经节神经元中分别减少钠电流17%(95% CI, 6-28%)和22%(95% CI, 9-35%)。
  • 腹腔和鞘内注射DA-0218分别减少福尔马林II相炎症痛行为76%(95% CI, 48-100%)和80%(95% CI, 68-92%)。

临床怎么用

  • DA-0218作为新型Nav1.7抑制剂,具有镇痛和抗瘙痒潜力,但尚未进入临床研究。

局限性

  • 研究仅在小鼠模型中进行,尚未在人体中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Voltage-gated sodium channel Nav1.7 has been validated as a perspective target for selective inhibitors with analgesic and anti-itch activity. The objective of this study was to discover new candidate compounds with Nav1.7 inhibitor properties. The authors hypothesized that their approach would yield at least one new compound that inhibits sodium currents in vitro and exerts analgesic and anti-itch effects in mice. METHODS: In silico structure-based similarity search of 1.5 million compounds followed by docking to the Nav1.7 voltage sensor of Domain 4 and molecular dynamics simulation was performed. Patch clamp experiments in Nav1.7-expressing human embryonic kidney 293 cells and in mouse and human dorsal root ganglion neurons were conducted to test sodium current inhibition. Formalin-induced inflammatory pain model, paclitaxel-induced neuropathic pain model, histamine-induced itch model, and mouse lymphoma model of chronic itch were used to confirm in vivo activity of the selected compound. RESULTS: After in silico screening, nine compounds were selected for experimental assessment in vitro. Of those, four compounds inhibited sodium currents in Nav1.7-expressing human embryonic kidney 293 cells by 29% or greater (P < 0.05). Compound 9 (3-(1-benzyl-1H-indol-3-yl)-3-(3-phenoxyphenyl)-N-(2-(pyrrolidin-1-yl)ethyl)propanamide, referred to as DA-0218) reduced sodium current by 80% with a 50% inhibition concentration of 0.74 μM (95% CI, 0.35 to 1.56 μM), but had no effects on Nav1.5-expressing human embryonic kidney 293 cells. In mouse and human dorsal root ganglion neurons, DA-0218 reduced sodium currents by 17% (95% CI, 6 to 28%) and 22% (95% CI, 9 to 35%), respectively. The inhibition was greatly potentiated in paclitaxel-treated mouse neurons. Intraperitoneal and intrathecal administration of the compound reduced formalin-induced phase II inflammatory pain behavior in mice by 76% (95% CI, 48 to 100%) and 80% (95% CI, 68 to 92%), respectively. Intrathecal administration of DA-0218 produced acute reduction in paclitaxel-induced mechanical allodynia, and inhibited histamine-induced acute itch and lymphoma-induced chronic itch. CONCLUSIONS: This study's computer-aided drug discovery approach yielded a new Nav1.7 inhibitor that shows analgesic and anti-pruritic activity in mouse models.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Chandra S, Wang Z, Tao X, et al. Computer-aided Discovery of a New Nav1.7 Inhibitor for Treatment of Pain and Itch. Anesthesiology. 2020. PMID: 32788559. doi:10.1097/ALN.0000000000003427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。